Treatment of microvascular invasion in hepatocellular carcinoma with drug‐loaded nanocomposite platform under synergistic effect of magnetic field/near‐infrared light
Source abstract
Abstract
Abstract Despite progress in clinical treatment, microvascular invasion (MVI) remains a major factor for frequent recurrence and metastasis of hepatocellular carcinoma (HCC) after liver resection and surgery. Thus, this study constructed a target nanoplatform (αCD97‐USPIO‐Au‐DDP) with magnetic field/near‐infrared (NIR) light response using ultrasmall superparamagnetic iron oxide‐gold nanoporous spheres (USPIO‐Au) as multifunctional nanocarrier. Anticancer drug cisplatin (DDP) was loaded, and specifically expressed CD97 protein in MVI was taken as the therapeutic target. The αCD97‐USPIO‐Au‐DDP showed favorable photothermal and stable properties under the NIR light at 808 nm wavelength. As suggested by in vitro and in vivo research, this composite nanopreparation could effectively reduce damage to normal organs and showed good biocompatibility. Excellent magnetic targeting function of nanocarrier and modification of αCD97 strengthened accumulation of composite nanodrug in tumor to inhibit tumor growth. This system may have important ramifications for treatment of MVI in HCC.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Extracellular vesicles in disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of General Surgery Second Affiliated Hospital, Zhejiang University Hangzhou China
Department of Radiology Second Affiliated Hospital, Zhejiang University Hangzhou China
Funding
Natural Science Foundation of Zhejiang Province
References (52)
Show source-provided references
1. 10.1016/j.addr.2014.10.02910.1016/j.addr.2014.10.029 ↗
2. 10.1016/j.tranon.2020.10087510.1016/j.tranon.2020.100875 ↗
3. 10.3322/caac.2149210.3322/caac.21492 ↗
4. 10.1016/S0140-6736(18)30010-210.1016/S0140-6736(18)30010-2 ↗
5. 10.1016/j.pdpdt.2019.01.02710.1016/j.pdpdt.2019.01.027 ↗
6. 10.1097/00000658-200203000-0000910.1097/00000658-200203000-00009 ↗
7. 10.1097/SLA.000000000000074710.1097/SLA.0000000000000747 ↗
8. 10.1245/s10434-012-2513-110.1245/s10434-012-2513-1 ↗
9. 10.1016/j.jamcollsurg.2017.09.00310.1016/j.jamcollsurg.2017.09.003 ↗
10. 10.1186/s12885-017-3050-x10.1186/s12885-017-3050-x ↗
11. 10.1021/pr301181510.1021/pr3011815 ↗
12. Role of CD97 isoforms in gastric carcinoma
13. 10.1039/c6nr08507e10.1039/c6nr08507e ↗
14. 10.1038/nrc156610.1038/nrc1566 ↗
15. 10.1016/j.jconrel.2014.12.03010.1016/j.jconrel.2014.12.030 ↗
16. 10.1039/c5bm00077g10.1039/c5bm00077g ↗
17. 10.2217/nnm-2017-033610.2217/nnm-2017-0336 ↗
18. 10.1002/wnan.147110.1002/wnan.1471 ↗
19. 10.1016/j.nano.2020.10228110.1016/j.nano.2020.102281 ↗
20. 10.1016/j.ejpb.2020.08.00410.1016/j.ejpb.2020.08.004 ↗
21. 10.1002/adma.20170430710.1002/adma.201704307 ↗
22. 10.1002/smll.20150227310.1002/smll.201502273 ↗
23. 10.1021/acsnano.8b0390010.1021/acsnano.8b03900 ↗
24. 10.1016/S0002-9440(10)64443-410.1016/S0002-9440(10)64443-4 ↗
25. 10.1210/jcem.84.3.555710.1210/jcem.84.3.5557 ↗
26. 10.1136/mp.55.3.19310.1136/mp.55.3.193 ↗
27. 10.3892/ijo.2013.207510.3892/ijo.2013.2075 ↗
28. 10.1371/journal.pone.003998910.1371/journal.pone.0039989 ↗
29. 10.1084/jem.2019059810.1084/jem.20190598 ↗
30. 10.3390/ijms2116565610.3390/ijms21165656 ↗
31. 10.1172/JCI12339610.1172/JCI123396 ↗
32. 10.1002/hep.3006810.1002/hep.30068 ↗
33. 10.1038/nmat125110.1038/nmat1251 ↗
34. 10.1002/ejic.20150026710.1002/ejic.201500267 ↗
35. 10.1016/j.cej.2019.12254010.1016/j.cej.2019.122540 ↗
36. 10.3389/fphar.2018.0107710.3389/fphar.2018.01077 ↗
37. 10.1111/j.1349-7006.2006.00276.x10.1111/j.1349-7006.2006.00276.x ↗
38. 10.1111/cas.1262410.1111/cas.12624 ↗
39. 10.1021/ja073057v10.1021/ja073057v ↗
40. 10.1016/j.jinorgbio.2020.11125810.1016/j.jinorgbio.2020.111258 ↗
41. Multifunctional Fe3O4 cluster@ quantum dot‐embedded mesoporous SiO2 nanoplatform probe for cancer cell fluorescence‐labelling detection and photothermal therapy
42. 10.1002/anie.20100318510.1002/anie.201003185 ↗
43. 10.1016/j.saa.2017.01.00810.1016/j.saa.2017.01.008 ↗
44. 10.1016/j.actbio.2021.07.02310.1016/j.actbio.2021.07.023 ↗
45. 10.1039/c4tb01189a10.1039/c4tb01189a ↗
46. 10.1016/j.jmmm.2013.04.06210.1016/j.jmmm.2013.04.062 ↗
47. 10.1016/j.cej.2020.12636410.1016/j.cej.2020.126364 ↗
48. 10.1002/adma.20120461610.1002/adma.201204616 ↗
49. 10.1016/j.procbio.2020.08.00910.1016/j.procbio.2020.08.009 ↗
50. 10.1016/j.biopha.2017.03.01210.1016/j.biopha.2017.03.012 ↗
51. 10.1016/j.msec.2020.11180810.1016/j.msec.2020.111808 ↗
52. 10.1016/j.jconrel.2021.05.01310.1016/j.jconrel.2021.05.013 ↗